Eris Lifesciences stock | Price, analyst rating, price target & growth

Eris Lifesciences

NSEI:ERIS

Rp 1.336,10

Rp0,00 (0,00%)

1.336,10 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Eris Lifesciences Stock Value

Analysts currently give NSEI:ERIS a rating of Buy.

Buy

Eris Lifesciences Company Info

EPS Growth 5Y

3,64%

Market Cap

Rp185,11 B

Long-Term Debt

Rp17,38 B

Annual earnings

05/19/2026 (E)

Dividend

Rp7,35

Dividend Yield

0,55%

Founded

2007

Industry

Health Care

Country

India

Website

Eris Lifesciences

ISIN Number

INE406M01024

Website

http://www.eris.co.in

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp1.773,00

32.7%

Last Update: 03/28/2026

Analysts: 10

Highest Price Target Rp1.940,00

Average Price Target Rp1.773,00

Lowest Price Target Rp1.520,00

In the last five quarters, Eris Lifesciences’s Price Target has risen from Rp760,67 to Rp993,89 - a 30,66% increase. Nine analysts predict that Eris Lifesciences’s share price will increase in the coming year, reaching Rp1.773,00. This would represent an increase of 32,70%.

Top growth stocks in the health care sector (5Y.)

What does Eris Lifesciences do?

Eris Lifesciences Limited operates in the pharmaceutical industry, specializing in the research, development, and manufacturing of high-quality pharmaceutical products. The company's primary focus is on the chronic therapy segments including diabetes, cardiology, and central nervous system disorders. Business Segments The company functions within several core business segments, each designed to enhance its operational reach and effectiveness in providing healthcare solutions. The company's key...

Business Segments

The company functions within several core business segments, each designed to enhance its operational reach and effectiveness in providing healthcare solutions. The company's key segments include:

Chronic Therapy Products: This segment is dedicated to the management of chronic diseases such as diabetes and cardiovascular conditions. The company manufactures a variety of medication aims at helping patients manage their health over extended periods, enhancing quality of life for those affected by these conditions.

Generics: This segment focuses on the development and distribution of generic pharmaceuticals, making essential medications more affordable and accessible. The generic products are manufactured through processes that meet high quality and regulatory standards.

Pharmaceutical R&D: The company invests significantly in research and development to foster innovation and bring new products to the market. The R&D efforts ensure that the company remains at the forefront of pharmaceutical advancements, catering to the changing needs of patients and healthcare professionals.

Specialty Divisions: These segments provide specialized healthcare solutions, focusing on niche therapeutic areas that require tailored products and strategies.

Manufacturing and Quality Assurance: The company places a strong emphasis on manufacturing processes that adhere to the highest quality assurance standards.

Business Strategy

The company has a clear and focused business strategy centered on growth, innovation, and sustainability. The company's strategic objectives include:

Expanding Market Reach: By strategically diversifying its product portfolio and entering new markets, the company aims to provide comprehensive healthcare solutions. This includes targeting under-served therapeutic areas and expanding geographical presence to capture new customer bases.

Innovation in Research: Continuous investment in research and development is at the heart of the company's strategy. By fostering an innovative culture and leveraging cutting-edge technologies, the company strives to develop ground-breaking products that meet the evolving needs of patients and healthcare providers.

Strengthening Quality Control: Maintaining the highest standards of quality assurance and regulatory compliance is fundamental to the company's strategy. The company consistently reviews and enhances its quality control processes to ensure the safety and efficacy of its products.

Enhancing Stakeholder Engagement: The company believes in building strong relationships with healthcare professionals and patients. This involves engaging with stakeholders to better understand their needs and concerns, enabling the company to adapt its offerings accordingly.

Sustainable Practices: The commitment to sustainability is reflected in the company's operational practices. The company integrates sustainable methods into its manufacturing processes while adhering to environmental regulations and promoting responsible business practices.

Products and Services

The company offers a comprehensive range of products and services aims at addressing various healthcare needs. The portfolio includes:

Prescription Pharmaceuticals: This category encompasses a vast array of formulations aims at treating chronic conditions such as diabetes, cardiovascular diseases, and neurological disorders.

Over the Counter (OTC) Products: The company provides a selection of OTC products designed for easier access by patients. These products cater to a variety of common health issues, thereby improving patient compliance and access to care.

Therapeutic Solutions: The company specializes in products that offer innovative therapeutic solutions tailored to specific patient needs. This includes advanced formulations and combination therapies aimed at enhancing treatment outcomes.

Patient Support Services: In addition to its medicinal offerings, the company also provides support services that include educational resources for healthcare professionals and patients. This emphasis on patient education aims to ensure responsible product usage and improved health management.

Research Collaboration: The company actively engages in research and development collaborations, seeking partnerships that foster innovation and advance scientific knowledge within the pharmaceutical realm.

Geographical Markets Served

The company extends its presence across various geographical markets, with a strong emphasis on India. Within this market, the company serves urban and semi-urban areas, ensuring a wide-ranging distribution network that enhances product accessibility. The company has plans for further geographic expansion both within India and internationally, allowing it to tap into emerging markets with growing healthcare needs.

Seasonality

However, certain therapeutic areas may experience variations due to seasonal patterns. For example, the demand for specific medications may increase during times of the year due to seasonal health trends.

Customers

The company serves a diverse customer base that includes healthcare professionals, hospitals, and pharmacies. The company caters to a broad spectrum of patient demographics, ensuring that its products are accessible across different segments of society.

Sales and Marketing

The company employs a multi-channel approach to marketing and sales, utilizing both traditional and digital platforms. This strategy enables the company to effectively reach its target audience and communicate product benefits succinctly.

Marketing efforts are supported by comprehensive market research that informs the company of patient and healthcare professional needs and preferences. Engagement with healthcare providers through educational initiatives further enhances product awareness and understanding.

The company distributes its products through a well-established network of pharmacies, hospitals, and healthcare institutions, ensuring efficient delivery and accessibility of its pharmaceutical offerings.

History

Eris Lifesciences Limited was founded in 2007. The company was incorporated in 2007.

Eris Lifesciences Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2026) **Top 3 Markets:** 1. **India:** approximately 90% 2. **Southeast Asia:** approximately 5% 3. **Africa:** approximately 3% Eris Lifesciences Limited generates the majority of its sales from the pharmaceutical industry, with the Indian market accounting for the...

At which locations are the company’s products manufactured?

**Production Sites:** Ahmedabad, Gujarat, India Eris Lifesciences Limited primarily produces its pharmaceutical products in Ahmedabad, Gujarat. This production facility specializes in formulation manufacturing and plays a central role in the company's supply chain. The company places great em...

What strategy does Eris Lifesciences pursue for future growth?

**Revenue Growth:** 10% (estimated for 2026) **Focus on Research and Development:** Eris Lifesciences is increasing its investment in research and development to bring innovative products to the market. This includes both expanding the existing product portfolio and developing new medications. **M...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), excipients **Countries of origin:** China, India, Europe Eris Lifesciences Limited mainly imports active pharmaceutical ingredients (APIs) and excipients needed for the production of their medicines. A significant portion of these r...

How strong is the company’s competitive advantage?

**Market share:** 3.5% in the Indian pharmaceutical market (2025) **Revenue growth:** 10% (2025) **EBITDA margin:** 32% (2025) Eris Lifesciences Limited has established itself as a significant player in the Indian pharmaceutical market, especially in the cardiovascular and diabetology medication...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 25% (2026, estimated) **Insider Buys/Sells:** No significant transactions in the last year The institutional investor share in Eris Lifesciences Limited is estimated to be around 25%. This figure reflects the confidence of institutional investors in...

What percentage market share does Eris Lifesciences have?

**Market share of Eris Lifesciences Limited:** 3.5% (estimated, 2026) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries Ltd.:** 8.2% 2. **Cipla Ltd.:** 7.5% 3. **Dr. Reddy's Laboratories Ltd.:** 6.9% 4. **Aurobindo Pharma Ltd.:** 5.8% 5. **Lupin Ltd.:** 5.2% 6. **...

Is Eris Lifesciences stock currently a good investment?

**Revenue Growth:** 10.5% (2025) **Profit Growth:** 8.2% (2025) **Research & Development Expenses:** 6% of revenue (2025) Eris Lifesciences Limited recorded a solid revenue growth of 10.5% in 2025, attributed to a strong product pipeline and successful market launches. The profit growth of 8.2%...

Does Eris Lifesciences pay a dividend – and how reliable is the payout?

**Dividend Yield:** 1.5% (estimated for 2026) Eris Lifesciences Limited has regularly paid out dividends in the past. The dividend yield has remained stable at around 1.5% in recent years. This demonstrates a certain reliability in the company's dividend distribution policy. The company has a...

New support ticket

Explore

Eris Lifesciences Stock Value

Eris Lifesciences Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Eris Lifesciences do?

Eris Lifesciences Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Eris Lifesciences Stock Value

Eris Lifesciences Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Eris Lifesciences do?

Eris Lifesciences Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.